The US Patent and Trademark Office (USPTO) has granted EndoSphere a patent that covers the use of its endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes.
US patent number 7,931,693 titled ‘Method and Apparatus for Reducing Obesity’ describes a noninvasive device that uses the body’s natural physiology to regulate appetite and satiety among other potential uses.
EndoSphere CEO James McKinley said this initial patent position, in combination with clinical interest, makes EndoSphere a partner in the fields of interventional gastroenterology and obesity treatments.
EndoSphere co-founder and the technology inventor Kenneth Binmoeller said EndoSphere’s inventions respond to the need for a less invasive, safer and physiologic treatment for the growing problem of obesity.
The company also develops devices including the SatiSphere duodenal insert, which treats obesity and its co-morbidities.